Your browser doesn't support javascript.
loading
A Novel Recurrent COL5A1 Genetic Variant Is Associated With a Dysplasia-Associated Arterial Disease Exhibiting Dissections and Fibromuscular Dysplasia.
Richer, Julie; Hill, Hannah L; Wang, Yu; Yang, Min-Lee; Hunker, Kristina L; Lane, Jamie; Blackburn, Susan; Coleman, Dawn M; Eliason, Jonathan; Sillon, Guillaume; D'Agostino, Maria-Daniela; Jetty, Prasad; Mongeon, François-Pierre; Laberge, Anne-Marie; Ryan, Stephen E; Fendrikova-Mahlay, Natalia; Coutinho, Thais; Mathis, Michael R; Zawistowski, Matthew; Hazen, Stanley L; Katz, Alexander E; Gornik, Heather L; Brummett, Chad M; Abecasis, Goncalo; Bergin, Ingrid L; Stanley, James C; Li, Jun Z; Ganesh, Santhi K.
Afiliação
  • Richer J; Department of Medical Genetics, Children's Hospital of Eastern Ontario, Ottawa, Canada (J.R.).
  • Hill HL; Department of Medical Genetics, Children's Hospital of Eastern Ontario, Ottawa, Canada (J.R.).
  • Wang Y; Division of Cardiovascular Medicine, Department of Internal Medicine (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Yang ML; Division of Cardiovascular Medicine, Department of Internal Medicine (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Hunker KL; Department of Human Genetics (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., J.Z.L., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Lane J; Division of Cardiovascular Medicine, Department of Internal Medicine (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Blackburn S; Department of Human Genetics (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., J.Z.L., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Coleman DM; Division of Cardiovascular Medicine, Department of Internal Medicine (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Eliason J; Department of Human Genetics (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., J.Z.L., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Sillon G; Division of Cardiovascular Medicine, Department of Internal Medicine (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • D'Agostino MD; Department of Human Genetics (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., J.Z.L., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Jetty P; Clinical Trials Unit-Heart Vessel (S.B.), University of Michigan Medical School, Ann Arbor.
  • Mongeon FP; Section of Vascular Surgery, Department of Surgery (D.M.C., J.E., J.C.S.), University of Michigan Medical School, Ann Arbor.
  • Laberge AM; Section of Vascular Surgery, Department of Surgery (D.M.C., J.E., J.C.S.), University of Michigan Medical School, Ann Arbor.
  • Ryan SE; Division of Medical Genetics, Departments of Specialized Medicine and Human Genetics, McGill University, Montreal, Quebec, Canada (G.S., M.-D.D.).
  • Fendrikova-Mahlay N; Division of Medical Genetics, Departments of Specialized Medicine and Human Genetics, McGill University, Montreal, Quebec, Canada (G.S., M.-D.D.).
  • Coutinho T; Division of Vascular Surgery (P.J.), University of Ottawa, ON, Canada.
  • Mathis MR; Division of Non Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute, Université de Montréal, Quebec, Canada (F.-P.M.).
  • Zawistowski M; Medical Genetics, Department of Pediatrics, CHU Ste-Justine, and Université de Montréal, Quebec, Canada (A.-M.L.).
  • Hazen SL; Department of Radiology (S.E.R.), University of Ottawa, ON, Canada.
  • Katz AE; Heart and Vascular Institute (N.F.-M., S.L.H., H.L.G.), Cleveland Clinic, OH.
  • Gornik HL; Division of Cardiology and Division of Cardiac Prevention and Rehabilitation, University of Ottawa Heart Institute, ON, Canada (T.C.).
  • Brummett CM; Department of Anesthesiology, Michigan Medicine, University of Michigan, Ann Arbor (M.R.M., C.M.B.).
  • Abecasis G; Department of Biostatistics and Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor (M.Z., G.A.).
  • Bergin IL; Heart and Vascular Institute (N.F.-M., S.L.H., H.L.G.), Cleveland Clinic, OH.
  • Stanley JC; Lerner Research Institute (S.L.H.), Cleveland Clinic, OH.
  • Li JZ; Division of Cardiovascular Medicine, Department of Internal Medicine (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., S.K.G.), University of Michigan Medical School, Ann Arbor.
  • Ganesh SK; Department of Human Genetics (H.L.H., Y.W., M.-L.Y., K.L.H., J.L., A.E.K., J.Z.L., S.K.G.), University of Michigan Medical School, Ann Arbor.
Arterioscler Thromb Vasc Biol ; 40(11): 2686-2699, 2020 11.
Article em En | MEDLINE | ID: mdl-32938213
OBJECTIVE: While rare variants in the COL5A1 gene have been associated with classical Ehlers-Danlos syndrome and rarely with arterial dissections, recurrent variants in COL5A1 underlying a systemic arteriopathy have not been described. Monogenic forms of multifocal fibromuscular dysplasia (mFMD) have not been previously defined. Approach and Results: We studied 4 independent probands with the COL5A1 pathogenic variant c.1540G>A, p.(Gly514Ser) who presented with arterial aneurysms, dissections, tortuosity, and mFMD affecting multiple arteries. Arterial medial fibroplasia and smooth muscle cell disorganization were confirmed histologically. The COL5A1 c.1540G>A variant is predicted to be pathogenic in silico and absent in gnomAD. The c.1540G>A variant is on a shared 160.1 kb haplotype with 0.4% frequency in Europeans. Furthermore, exome sequencing data from a cohort of 264 individuals with mFMD were examined for COL5A1 variants. In this mFMD cohort, COL5A1 c.1540G>A and 6 additional relatively rare COL5A1 variants predicted to be deleterious in silico were identified and were associated with arterial dissections (P=0.005). CONCLUSIONS: COL5A1 c.1540G>A is the first recurring variant recognized to be associated with arterial dissections and mFMD. This variant presents with a phenotype reminiscent of vascular Ehlers-Danlos syndrome. A shared haplotype among probands supports the existence of a common founder. Relatively rare COL5A1 genetic variants predicted to be deleterious by in silico analysis were identified in ≈2.7% of mFMD cases, and as they were enriched in patients with arterial dissections, may act as disease modifiers. Molecular testing for COL5A1 should be considered in patients with a phenotype overlapping with vascular Ehlers-Danlos syndrome and mFMD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artérias / Polimorfismo de Nucleotídeo Único / Colágeno Tipo V / Síndrome de Ehlers-Danlos / Displasia Fibromuscular / Dissecção Aórtica Tipo de estudo: Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artérias / Polimorfismo de Nucleotídeo Único / Colágeno Tipo V / Síndrome de Ehlers-Danlos / Displasia Fibromuscular / Dissecção Aórtica Tipo de estudo: Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article